Inflammation-mediated genomic instability: Roles of activation-induced cytidine deaminase in carcinogenesis

Cancer Science

Volumn 103, Issue 7, 2012, Pages 1201-1206

  Shimizu, Takahiro ^a   Marusawa, Hiroyuki ^a   Endo, Yoko ^a   Chiba, Tsutomu ^a  

^a KYOTO UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ACTIVATION INDUCED CYTIDINE DEAMINASE; GAMMA INTERFERON; IMMUNOGLOBULIN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 12; PROTEIN KINASE PIM 1; TRANSCRIPTION FACTOR PAX5; TUMOR NECROSIS FACTOR ALPHA;

ADENOMATOUS POLYP; BARRETT ESOPHAGUS; CANCER INCIDENCE; CARCINOGENESIS; CHRONIC LIVER DISEASE; COLORECTAL CANCER; DISEASE ASSOCIATION; ENTERITIS; EPITHELIUM CELL; ESOPHAGEAL ADENOCARCINOMA; ESOPHAGUS CARCINOMA; GASTRITIS; GENE EXPRESSION; GENE MUTATION; GENOMIC INSTABILITY; HELICOBACTER INFECTION; HELICOBACTER PYLORI; HUMAN; IN VITRO STUDY; INFLAMMATION; LARGE CELL LYMPHOMA; LIVER CARCINOGENESIS; METAPLASIA; MOUTH INFECTION; PRIORITY JOURNAL; REVIEW; SOMATIC MUTATION; STOMACH CANCER; T LYMPHOCYTE; TRANSGENIC MOUSE; TUMOR GROWTH; TUMOR PROMOTION; UPREGULATION; VIRUS HEPATITIS;

ANIMALS; CELL TRANSFORMATION, NEOPLASTIC; CHROMOSOME ABERRATIONS; CYTIDINE DEAMINASE; DNA DAMAGE; GENOMIC INSTABILITY; HUMANS; INFLAMMATION; MODELS, GENETIC; MUTATION;

EID: 84863331610     PISSN: 13479032     EISSN: 13497006     Source Type: Journal    
DOI: 10.1111/j.1349-7006.2012.02293.x     Document Type: Review

References (73)

1. Vogelstein B, Kinzler KW. Cancer genes and the pathways they control. Nat Med 2004; 10: 789-99.
2. Meyerson M, Gabriel S, Getz G. Advances in understanding cancer genomes through second-generation sequencing. Nat Rev Genet 2010; 11: 685-96.
3. Bentley DR, Balasubramanian S, Swerdlow HP et al. Accurate whole human genome sequencing using reversible terminator chemistry. Nature 2008; 456: 53-9.
4. Ionov Y, Peinado MA, Malkhosyan S, Shibata D, Perucho M. Ubiquitous somatic mutations in simple repeated sequences reveal a new mechanism for colonic carcinogenesis. Nature 1993; 363: 558-61.
5. Fishel R, Lescoe MK, Rao MR et al. The human mutator gene homolog MSH2 and its association with hereditary nonpolyposis colon cancer. Cell 1993; 75: 1027-38.
6. Kiyosawa K, Umemura T, Ichijo T et al. Hepatocellular carcinoma: recent trends in Japan. Gastroenterology 2004; 127: S17-26.
7. Ikeda K, Marusawa H, Osaki Y et al. Antibody to hepatitis B core antigen and risk for hepatitis C-related hepatocellular carcinoma: a prospective study. Ann Intern Med 2007; 146: 649-56.
8. Chiba T, Seno H, Marusawa H, Wakatsuki Y, Okazaki K. Host factors are important in determining clinical outcomes of Helicobacter pylori infection. J Gastroenterol 2006; 41: 1-9.
9. Eaden JA, Abrams KR, Mayberry JF. The risk of colorectal cancer in ulcerative colitis: a meta-analysis. Gut 2001; 48: 526-35.
10. Fevery J, Verslype C. An update on cholangiocarcinoma associated with primary sclerosing cholangitis. Curr Opin Gastroenterol 2010; 26: 236-45.
11. Reid BJ, Li X, Galipeau PC, Vaughan TL. Barrett's oesophagus and oesophageal adenocarcinoma: time for a new synthesis. Nat Rev Cancer 2010; 10: 87-101.
12. Hussain SP, Harris CC. Inflammation and cancer: an ancient link with novel potentials. Int J Cancer 2007; 121: 2373-80.
13. Grivennikov SI, Greten FR, Karin M. Immunity, inflammation, and cancer. Cell 2010; 140: 883-99.
14. Karin M. Nuclear factor-kappaB in cancer development and progression. Nature 2006; 441: 431-6.
15. Viala J, Chaput C, Boneca IG et al. Nod1 responds to peptidoglycan delivered by the Helicobacter pylori cag pathogenicity island. Nat Immunol 2004; 5: 1166-74.
16. Elsharkawy AM, Mann DA. Nuclear factor-kappaB and the hepatic inflammation-fibrosis-cancer axis. Hepatology 2007; 46: 590-7.
17. Greten FR, Eckmann L, Greten TF et al. IKKbeta links inflammation and tumorigenesis in a mouse model of colitis-associated cancer. Cell 2004; 118: 285-96.
18. Pikarsky E, Porat RM, Stein I et al. NF-kappaB functions as a tumour promoter in inflammation-associated cancer. Nature 2004; 431: 461-6.
19. Ben-Neriah Y, Karin M. Inflammation meets cancer, with NF-kappaB as the matchmaker. Nat Immunol 2011; 12: 715-23.
20. Marusawa H, Takai A, Chiba T. Role of activation-induced cytidine deaminase in inflammation-associated cancer development. Adv Immunol 2011; 111: 109-41.
21. Cascalho M. Advantages and disadvantages of cytidine deamination. J Immunol 2004; 172: 6513-8.
22. Honjo T, Kinoshita K, Muramatsu M. Molecular mechanism of class switch recombination: linkage with somatic hypermutation. Annu Rev Immunol 2002; 20: 165-96.
23. Muramatsu M, Sankaranand VS, Anant S et al. Specific expression of activation-induced cytidine deaminase (AID), a novel member of the RNA-editing deaminase family in germinal center B cells. J Biol Chem 1999; 274: 18470-6.
24. Muramatsu M, Kinoshita K, Fagarasan S, Yamada S, Shinkai Y, Honjo T. Class switch recombination and hypermutation require activation-induced cytidine deaminase (AID), a potential RNA editing enzyme. Cell 2000; 102: 553-63.
25. Liu M, Schatz DG. Balancing AID and DNA repair during somatic hypermutation. Trends Immunol 2009; 30: 173-81.
26. Revy P, Muto T, Levy Y et al. Activation-induced cytidine deaminase (AID) deficiency causes the autosomal recessive form of the Hyper-IgM syndrome (HIGM2). Cell 2000; 102: 565-75.
27. Kotani A, Okazaki IM, Muramatsu M et al. A target selection of somatic hypermutations is regulated similarly between T and B cells upon activation-induced cytidine deaminase expression. Proc Natl Acad Sci USA 2005; 102: 4506-11.
28. Shen HM, Peters A, Baron B, Zhu X, Storb U. Mutation of BCL-6 gene in normal B cells by the process of somatic hypermutation of Ig genes. Science 1998; 280: 1750-2.
29. Liu M, Duke JL, Richter DJ et al. Two levels of protection for the B cell genome during somatic hypermutation. Nature 2008; 451: 841-5.
30. Pasqualucci L, Neumeister P, Goossens T et al. Hypermutation of multiple proto-oncogenes in B-cell diffuse large-cell lymphomas. Nature 2001; 412: 341-6.
31. Greeve J, Philipsen A, Krause K et al. Expression of activation-induced cytidine deaminase in human B-cell non-Hodgkin lymphomas. Blood 2003; 101: 3574-80.
32. Pasqualucci L, Guglielmino R, Houldsworth J et al. Expression of the AID protein in normal and neoplastic B cells. Blood 2004; 104: 3318-25.
33. Chiarle R, Zhang Y, Frock RL et al. Genome-wide translocation sequencing reveals mechanisms of chromosome breaks and rearrangements in B cells. Cell 2011; 147: 107-19.
34. Klein IA, Resch W, Jankovic M et al. Translocation-capture sequencing reveals the extent and nature of chromosomal rearrangements in B lymphocytes. Cell 2011; 147: 95-106.
35. Okazaki IM, Hiai H, Kakazu N et al. Constitutive expression of AID leads to tumorigenesis. J Exp Med 2003; 197: 1173-81.
36. Morisawa T, Marusawa H, Ueda Y et al. Organ-specific profiles of genetic changes in cancers caused by activation-induced cytidine deaminase expression. Int J Cancer 2008; 123: 2735-40.
37. Nagaoka H, Tran TH, Kobayashi M, Aida M, Honjo T. Preventing AID, a physiological mutator, from deleterious activation: regulation of the genomic instability that is associated with antibody diversity. Int Immunol 2010; 22: 227-35.
38. Yadav A, Olaru A, Saltis M, Setren A, Cerny J, Livak F. Identification of a ubiquitously active promoter of the murine activation-induced cytidine deaminase (AICDA) gene. Mol Immunol 2006; 43: 529-41.
39. Tran TH, Nakata M, Suzuki K et al. B cell-specific and stimulation-responsive enhancers derepress Aicda by overcoming the effects of silencers. Nat Immunol 2010; 11: 148-54.
40. Gourzi P, Leonova T, Papavasiliou FN. Viral induction of AID is independent of the interferon and the Toll-like receptor signaling pathways but requires NF-kappaB. J Exp Med 2007; 204: 259-65.
41. Pauklin S, Sernandez IV, Bachmann G, Ramiro AR, Petersen-Mahrt SK. Estrogen directly activates AID transcription and function. J Exp Med 2009; 206: 99-111.
42. Kou T, Marusawa H, Kinoshita K et al. Expression of activation-induced cytidine deaminase in human hepatocytes during hepatocarcinogenesis. Int J Cancer 2007; 120: 469-76.
43. Tai DI, Tsai SL, Chen YM et al. Activation of nuclear factor kappaB in hepatitis C virus infection: implications for pathogenesis and hepatocarcinogenesis. Hepatology 2000; 31: 656-64.
44. Marusawa H, Hijikata M, Chiba T, Shimotohno K. Hepatitis C virus core protein inhibits Fas- and tumor necrosis factor alpha-mediated apoptosis via NF-kappaB activation. J Virol 1999; 73: 4713-20.
45. Endo Y, Marusawa H, Kinoshita K et al. Expression of activation-induced cytidine deaminase in human hepatocytes via NF-kappaB signaling. Oncogene 2007; 26: 5587-95.
46. Peek RM Jr, Blaser MJ. Helicobacter pylori and gastrointestinal tract adenocarcinomas. Nat Rev Cancer 2002; 2: 28-37.
47. Aoi T, Marusawa H, Sato T, Chiba T, Maruyama M. Risk of subsequent development of gastric cancer in patients with previous gastric epithelial neoplasia. Gut 2006; 55: 588-9.
48. Fukase K, Kato M, Kikuchi S et al. Effect of eradication of Helicobacter pylori on incidence of metachronous gastric carcinoma after endoscopic resection of early gastric cancer: an open-label, randomised controlled trial. Lancet 2008; 372: 392-7.
49. Maehata Y, Nakamura S, Fujisawa K et al. Long-term effect of Helicobacter pylori eradication on the development of metachronous gastric cancer after endoscopic resection of early gastric cancer. Gastrointest Endosc 2012; 75: 39-46.
50. Matsumoto Y, Marusawa H, Kinoshita K et al. Helicobacter pylori infection triggers aberrant expression of activation-induced cytidine deaminase in gastric epithelium. Nat Med 2007; 13: 470-6.
51. Tomb JF, White O, Kerlavage AR et al. The complete genome sequence of the gastric pathogen Helicobacter pylori. Nature 1997; 388: 539-47.
52. Blaser MJ. Helicobacter pylori and gastric diseases. BMJ 1998; 316: 1507-10.
53. Peek RM Jr. IV. Helicobacter pylori strain-specific activation of signal transduction cascades related to gastric inflammation. Am J Physiol Gastrointest Liver Physiol 2001; 280: G525-30.
54. Keates S, Hitti YS, Upton M, Kelly CP. Helicobacter pylori infection activates NF-kappa B in gastric epithelial cells. Gastroenterology 1997; 113: 1099-109.
55. Matsumoto Y, Marusawa H, Kinoshita K, Niwa Y, Sakai Y, Chiba T. Up-regulation of activation-induced cytidine deaminase causes genetic aberrations at the CDKN2b-CDKN2a in gastric cancer. Gastroenterology 2010; 139: 1984-94.
56. Podolsky DK. Inflammatory bowel disease. N Engl J Med 2002; 347: 417-29.
57. Mellemkjaer L, Olsen JH, Frisch M, Johansen C, Gridley G, McLaughlin JK. Cancer in patients with ulcerative colitis. Int J Cancer 1995; 60: 330-3.
58. Jess T, Gamborg M, Matzen P, Munkholm P, Sorensen TI. Increased risk of intestinal cancer in Crohn's disease: a meta-analysis of population-based cohort studies. Am J Gastroenterol 2005; 100: 2724-9.
59. Fearon ER, Vogelstein B. A genetic model for colorectal tumorigenesis. Cell 1990; 61: 759-67.
60. Yin J, Harpaz N, Tong Y et al. p53 point mutations in dysplastic and cancerous ulcerative colitis lesions. Gastroenterology 1993; 104: 1633-9.
61. Kern SE, Redston M, Seymour AB et al. Molecular genetic profiles of colitis-associated neoplasms. Gastroenterology 1994; 107: 420-8.
62. Endo Y, Marusawa H, Kou T et al. Activation-induced cytidine deaminase links between inflammation and the development of colitis-associated colorectal cancers. Gastroenterology 2008; 135: 889-98, 98 e1-3.
63. Fuss IJ, Neurath M, Boirivant M et al. Disparate CD4+ lamina propria (LP) lymphokine secretion profiles in inflammatory bowel disease. Crohn's disease LP cells manifest increased secretion of IFN-gamma, whereas ulcerative colitis LP cells manifest increased secretion of IL-5. J Immunol 1996; 157: 1261-70.
64. Inoue S, Matsumoto T, Iida M et al. Characterization of cytokine expression in the rectal mucosa of ulcerative colitis: correlation with disease activity. Am J Gastroenterol 1999; 94: 2441-6.
65. Glocker EO, Kotlarz D, Boztug K et al. Inflammatory bowel disease and mutations affecting the interleukin-10 receptor. N Engl J Med 2009; 361: 2033-45.
66. Kuhn R, Lohler J, Rennick D, Rajewsky K, Muller W. Interleukin-10-deficient mice develop chronic enterocolitis. Cell 1993; 75: 263-74.
67. Berg DJ, Davidson N, Kuhn R et al. Enterocolitis and colon cancer in interleukin-10-deficient mice are associated with aberrant cytokine production and CD4(+) TH1-like responses. J Clin Invest 1996; 98: 1010-20.
68. Takai A, Marusawa H, Minaki Y et al. Targeting activation-induced cytidine deaminase prevents colon cancer development despite persistent colonic inflammation. Oncogene 2011; 31: 1733-42.
69. Kazumori H, Ishihara S, Kinoshita Y. Roles of caudal-related homeobox gene Cdx1 in oesophageal epithelial cells in Barrett's epithelium development. Gut 2009; 58: 620-8.
70. O'Riordan JM, Abdel-latif MM, Ravi N et al. Proinflammatory cytokine and nuclear factor kappa-B expression along the inflammation-metaplasia-dysplasia-adenocarcinoma sequence in the esophagus. Am J Gastroenterol 2005; 100: 1257-64.
71. Morita S, Matsumoto Y, Okuyama S et al. Bile acid-induced expression of activation-induced cytidine deaminase during the development of Barrett's oesophageal adenocarcinoma. Carcinogenesis 2011; 32: 1706-12.
72. Guo JU, Su Y, Zhong C, Ming GL, Song H. Hydroxylation of 5-methylcytosine by TET1 promotes active DNA demethylation in the adult brain. Cell 2011; 145: 423-34.
73. Cortellino S, Xu J, Sannai M et al. Thymine DNA glycosylase is essential for active DNA demethylation by linked deamination-base excision repair. Cell 2011; 146: 67-79.